AZD 4017

Drug Profile

AZD 4017

Alternative Names: AZD4017

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; University of Birmingham
  • Class Antihyperglycaemics
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors; 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pseudotumour cerebri
  • Discontinued Glaucoma; Obesity; Ocular hypertension; Type 2 diabetes mellitus

Most Recent Events

  • 07 Feb 2014 Biomarkers information updated
  • 31 Jan 2014 University of Birmingham plans a phase II trial for Pseudotumour cerebri in UK (NCT02017444)
  • 31 Dec 2012 Discontinued - Phase-II for Glaucoma in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top